MYH7 sirna

MYH7 siRNA (Rat)

Cat. Num. AAA8240293

• Gene Names: Myh7; Bmyo; Myhcb; myHC-beta; myHC-slow
• Reactivity: Rat
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: MYH7; MYH7 siRNA (Rat); Myosin-7; Myosin heavy chain 7; Myosin heavy chain slow isoform; MyHC-slow; Myosin heavy chain. cardiac muscle beta isoform; MyHC-beta; MYH7 sirna

• Host: Synthetic
• Reactivity: Rat
• Specificity: MYH7 siRNA (Rat) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 1935

• Applicable Applications for MYH7 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of rat MYH7 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for MYH7 sirna

siRNA to inhibit MYH7 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 8393807
• NCBI GeneID: 29557
• NCBI Accession #: NP_058936.1
• NCBI GenBank Nucleotide #: NM_017240.2
• UniProt Accession #: P02564
• Molecular Weight: 223,083 Da
• NCBI Official Full Name: myosin-7
• NCBI Official Synonym Full Names: myosin, heavy chain 7, cardiac muscle, beta
• NCBI Official Symbol: Myh7
• NCBI Official Synonym Symbols: Bmyo; Myhcb; myHC-beta; myHC-slow
• NCBI Protein Information: myosin-7
• UniProt Protein Name: Myosin-7
• Protein Family: Myosin
• UniProt Gene Name: Myh7
• UniProt Synonym Gene Names: MyHC-slow; MyHC-beta
• UniProt Entry Name: MYH7_RAT

NCBI Description

heavy chain of myosin; involved in muscle contraction [RGD, Feb 2006]

Uniprot Description

MYH7: Muscle contraction. Defects in MYH7 are the cause of familial hypertrophic cardiomyopathy type 1 (CMH1). Familial hypertrophic cardiomyopathy is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. Defects in MYH7 are the cause of myopathy myosin storage (MYOMS). In this disorder, muscle biopsy shows type 1 fiber predominance and increased interstitial fat and connective tissue. Inclusion bodies consisting of the beta cardiac myosin heavy chain are present in the majority of type 1 fibers, but not in type 2 fibers. Defects in MYH7 are the cause of scapuloperoneal myopathy MYH7-related (SPMM); also known as scapuloperoneal syndrome myopathic type. SPMM is a progressive muscular atrophia beginning in the lower legs and affecting the shoulder region earlier and more severely than distal arm. Defects in MYH7 are a cause of cardiomyopathy dilated type 1S (CMD1S). Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. Defects in MYH7 are the cause of myopathy distal type 1 (MPD1). MPD1 is a muscular disorder characterized by early-onset selective weakness of the great toe and ankle dorsiflexors, followed by weakness of the finger extensors. Mild proximal weakness occasionally develops years later after the onset of the disease.

Protein type: Motor; Motility/polarity/chemotaxis

Cellular Component: nucleoplasm; focal adhesion; myofibril; cytoplasm; stress fiber; muscle myosin complex; myosin complex; nucleus; Z disc

Molecular Function: microfilament motor activity; calmodulin binding; protein homodimerization activity; protein heterodimerization activity; ATPase activity; actin binding; actin-dependent ATPase activity; ATP binding

Biological Process: adult heart development; transition between fast and slow fiber; response to reactive oxygen species; striated muscle contraction; muscle contraction; regulation of heart rate; metabolic process; ventricular cardiac muscle morphogenesis; regulation of the force of heart contraction; muscle filament sliding